TEWKSBURY, Mass.--(BUSINESS WIRE)--Cambridge Heart, Inc. (OTCBB: CAMH), a developer of non-invasive diagnostic tests for cardiac disease, today announced that its Microvolt T-Wave Alternans (MTWA) test was recently featured in Diagnostic and Interventional Cardiology (DAIC) as the Case of the Week.
The clinical case illustrates the prognostic value of the test in a patient who received an implantable cardioverter defibrillator (ICD) after testing positive for MTWA. One year later, the patient experienced sudden cardiac arrest (SCA) while resting at home and was revived by a shock from the device. “This patient would not have received life-saving ICD therapy if he had not undergone an MTWA study,” noted Dr. Keith G. Boman, the patient’s cardiologist. “MTWA is a tool to help clarify the overall arrhythmic risk, particularly for patients who fall into a ‘gray area’ in terms of ICD eligibility.”
“This is a powerful real-world example of how MTWA can benefit patients by providing a unique piece of diagnostic information,” says Dr. Ali Haghighi-Mood, CEO of Cambridge Heart.
The case study can be found on the DAIC website at: http://www.dicardiology.net/node/39134/
Diagnostic & Interventional Cardiology is the widest-reaching provider of new product information, technology trends, application strategies and related connectivity solutions in the diagnostic and interventional cardiology markets.
Sudden cardiac arrest claims 300,000 lives in the United States each year. Out-of-hospital survival is less than 8%, making prediction and prevention critically important. Microvolt T-Wave Alternans is a marker of SCA risk which is measured from the electrocardiogram (ECG) recorded during a non-invasive treadmill test.
About Cambridge Heart, Inc.
Cambridge Heart develops and commercializes non-invasive diagnostic tests for cardiac disease, with a focus on identifying those at risk for sudden cardiac arrest (SCA). The Company’s products incorporate proprietary Microvolt T-Wave Alternans™ measurement technologies, including the patented Analytic Spectral Method® and ultrasensitive disposable electrode sensors. The Company’s MTWA test, originally based on research conducted at the Massachusetts Institute of Technology, is reimbursed by Medicare under its National Coverage Policy.
Cambridge Heart, founded in 1990, is based in Tewksbury, MA. It is traded on the Over-The-Counter Bulletin Board (OTCBB) under the symbol CAMH.OB.
http://www.cambridgeheart.com.
Statements contained in this press release that are not purely historical are forward-looking statements for purposes of the safe harbor provisions under The Private Securities Litigation Reform Act of 1995. In some cases, we use words such as “believes”, “expects”, “anticipates”, “plans”, “estimates”, “could”, and similar expressions that convey uncertainty of future events or outcomes to identify these forward-looking statements. Actual results may differ materially from those indicated by these forward-looking statements. Factors that may cause or contribute to such differences are identified in our most recent Annual Report on Form 10-K under “Risk Factors”, which is on file with the SEC and available at www.EDGAR.com. In addition, any forward-looking statements represent our estimates only as of today and should not be relied upon as representing our estimates as of any subsequent date. While we may elect to update forward-looking statements at some point in the future, we specifically disclaim any obligation to do so except as may be legally necessary, even if our estimates should change.